Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

08:00 - 08:50 50 mins
08:50 - 09:00 10 mins
Chairman's Opening Remarks
09:00 - 10:00 60 mins
Microbiome Therapeutics Europe
Approaching the Human Body Differently: Microbiome Therapeutic areas and moving the path forward
  • Ricardo Valladares - Vice President, Research & Development, Siolta Therapeutics

The Microbiome is one of the hottest areas of personalized medicine being studied. Experts in pharma, biotech, and investors are checking out how they can be a part of this emerging space – and what discoveries are next.

Clinical development and research in multiple therapeutic areas, including allergies, infant health, and microbiome discovery and application beyond the gut.

Learn what is being done to steer the relevance and future direction of the human microbiome frontier.

10:00 - 10:30 30 mins
Microbiome Therapeutics Europe
Early life Microbiome Development: the Interaction of Fungal Species with Diet and Bacteria
  • Wouter De Jonge - Professor of NeuroGastroenterology, AMC Amsterdam

- Case study: Early life microbiome development, focusing on the part of the microbiome that concern fungi in pre-term children, and correlated fungal and bacterial composition to health risks such as NEC and sepsis.

- Explore key findings in the implication of pre-term birth, the extensive use of antibiotics in early life, and fungi composition in the early life intestinal compartment, highlighting the mechanistic elements of fungi-epithelial function which is relevant for later risks of immune mediated chronic diseases in adulthood.

- Consider project lines on microbiota predictive biomarkers in postoperative ileus and anastomotic leakage, in adult patients.

10:30 - 11:00 30 mins
Microbiome Therapeutics Europe
Morning Coffee and Networking
11:00 - 11:45 45 mins
Microbiome Therapeutics Europe
Single-cell dispensing technology – a new tool for isolation and cultivation
  • Julian Riba - CSO, Cytena

- Get to grips with technology for label-free cell isolation: B.sight, a benchtop instrument for automated isolation of prokaryotic cells, single-cell dispensing technology

- Examine how B.sight can be used to isolate single bacteria from heterogeneous samples such as faeces or sputum for subsequent clonal cultivation or single-cell sequencing

- Explore how this technology could be an ideal tool for isolation and cultivation of potentially unknown microbial species

11:45 - 12:15 30 mins
Microbiome Therapeutics Europe
PARAGEN a unique collection of synthetic gene library to modulate microbiome composition
  • Philippe Gabant - CSO - Founder, SYNGULON

Microbiome equilibrium is more and more linked to different aspects of human health. Modification of the human microbiome(s) is one of the next challenge of modern medicine. There is a clear need foe new compounds allowing to tune microbiome bacterial population.

PARAGEN is a unique collection of bacteriocin (natural antimicrobial peptides) genes generated by synthetic biology. Using this collection it is possible to generate active bacteriocins and cocktails of bacteriocins.

Bacteria in their natural ecosystem are secreting bacteriocins to control the growth of microbes present in their ecological niche. For the first time the PARAGEN collection give access to a unique set of bacteriocins that could be applied to study and/or tune microbiota.

12:15 - 13:15 60 mins
Microbiome Therapeutics Europe
Lunch and Networking
13:15 - 13:45 30 mins
Microbiome Therapeutics Europe
Engineering the Microbiome: Targeted Bacterial CRISP-Cas proteins
  • Xavier Duportet - CEO, Eligo Bioscience

This talk will cover the disruptive approach into engineering the microbiome by delivering genetic circuit expressing CRISP-Cas or other proteins into targeted bacterial populations of the microbiome.

13:45 - 14:30 45 mins
Microbiome Therapeutics Europe
How can we talk about health care when we don't understand health and we don't care?
  • Larry Weiss - CEO & Founder, Persona Biome

The emerging science of the microbiome is still in its infancy yet it is the driving force behind a transformative scientific revolution. 

- What lies ahead in the field of microbiome therapeutics will have broad implications for scientists, companies and academic institutions, our health, and perhaps for our survival.

- It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision.

- Case Study: Examine microbiome data from recent Amazon studies of minimally impacted Yanomami hunter-gatherers and discuss what's been learnt about our (humans) biological past that is challenging deeply held ideas about human health.

14:30 - 15:00 30 mins
Microbiome Therapeutics Europe
Microbiome Reference Standards: A Path from Research to Therapeutics Through Higher Quality of Data
  • Raul Cano - CSO, The BioCollective

The microbial community needs validated measurements that accurately describe various properties, both quantitatively and qualitatively.

- Discover new bio-markers that may serve as disease indicators and to understand biologically-relevant properties of the human gut microbiome.

- The availability and compulsory use of the whole stool gut microbiome reference material as well as other reference materials would enable researchers to advance microbiome science through measurement assurance further and faster. While some efforts are currently moving in this direction directed in this area, no clear consensus on methods and criteria for control reagents exists.

- Examine the current state-of-the-art and novel products in the pipeline as well as suggested uses and scope of applications.

15:00 - 15:30 30 mins
Microbiome Therapeutics Europe
Coffee and Networking
15:30 - 16:00 30 mins
Microbiome Therapeutics Europe
The status of microbiome-derived therapeutics, R&D, new technologies and applications
  • Michel de Baar - Executive Director, Business Development, Europe, MSD

Clinical development and research are advancing at a rapid pace, but multiple questions need to be answered:

  • What is the status of the latest human microbiome therapeutics discoveries and what do they mean for the industry?
  • Which technologies are being used in clinical stages of microbiome studies?
  • What is next on the horizon for microbiome beyond the gut?
16:00 - 17:00 60 mins
Microbiome Therapeutics Europe
Showcase Spotlight
17:00 - 18:00 60 mins
Networking Drinks Reception
18:00 - 18:05 5 mins
End of Conference Day 1